Clinical Trial: Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07069699) titled 'Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene' on July 16.

Brief Summary: This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma. CX-5461 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CX-5461 may be safe, tolerable and/or effective in treating patients with B-cell non-Hodgkin lymphoma.

Study Start Date: Sept. 19

Study Type: INTERVENTIONAL

Condition: Burkitt Lymphoma Double-Expressor Lymphoma High G...